Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor.

Zelcer N, Hong C, Boyadjian R, Tontonoz P.

Science. 2009 Jul 3;325(5936):100-4. doi: 10.1126/science.1168974. Epub 2009 Jun 11.

2.

Targeted disruption of the idol gene alters cellular regulation of the low-density lipoprotein receptor by sterols and liver x receptor agonists.

Scotti E, Hong C, Yoshinaga Y, Tu Y, Hu Y, Zelcer N, Boyadjian R, de Jong PJ, Young SG, Fong LG, Tontonoz P.

Mol Cell Biol. 2011 May;31(9):1885-93. doi: 10.1128/MCB.01469-10. Epub 2011 Feb 22.

3.

Feedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axis.

Zhang L, Reue K, Fong LG, Young SG, Tontonoz P.

Arterioscler Thromb Vasc Biol. 2012 Nov;32(11):2541-6. doi: 10.1161/ATVBAHA.112.250571. Epub 2012 Aug 30. Review.

4.

Deubiquitylase Inhibition Reveals Liver X Receptor-independent Transcriptional Regulation of the E3 Ubiquitin Ligase IDOL and Lipoprotein Uptake.

Nelson JK, Cook EC, Loregger A, Hoeksema MA, Scheij S, Kovacevic I, Hordijk PL, Ovaa H, Zelcer N.

J Biol Chem. 2016 Feb 26;291(9):4813-25. doi: 10.1074/jbc.M115.698688. Epub 2015 Dec 30.

5.

The E3 ubiquitin ligase IDOL induces the degradation of the low density lipoprotein receptor family members VLDLR and ApoER2.

Hong C, Duit S, Jalonen P, Out R, Scheer L, Sorrentino V, Boyadjian R, Rodenburg KW, Foley E, Korhonen L, Lindholm D, Nimpf J, van Berkel TJ, Tontonoz P, Zelcer N.

J Biol Chem. 2010 Jun 25;285(26):19720-6. doi: 10.1074/jbc.M110.123729. Epub 2010 Apr 28.

6.

Post-transcriptional regulation of lipoprotein receptors by the E3-ubiquitin ligase inducible degrader of the low-density lipoprotein receptor.

Sorrentino V, Zelcer N.

Curr Opin Lipidol. 2012 Jun;23(3):213-9. doi: 10.1097/MOL.0b013e3283532947. Review.

PMID:
22510808
7.

The LXR-IDOL axis defines a clathrin-, caveolae-, and dynamin-independent endocytic route for LDLR internalization and lysosomal degradation.

Sorrentino V, Nelson JK, Maspero E, Marques AR, Scheer L, Polo S, Zelcer N.

J Lipid Res. 2013 Aug;54(8):2174-84. doi: 10.1194/jlr.M037713. Epub 2013 Jun 3.

8.

Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.

Sasaki M, Terao Y, Ayaori M, Uto-Kondo H, Iizuka M, Yogo M, Hagisawa K, Takiguchi S, Yakushiji E, Nakaya K, Ogura M, Komatsu T, Ikewaki K.

Arterioscler Thromb Vasc Biol. 2014 Jun;34(6):1171-8. doi: 10.1161/ATVBAHA.113.302670. Epub 2014 Mar 27.

9.

The Deubiquitylase USP2 Regulates the LDLR Pathway by Counteracting the E3-Ubiquitin Ligase IDOL.

Nelson JK, Sorrentino V, Avagliano Trezza R, Heride C, Urbe S, Distel B, Zelcer N.

Circ Res. 2016 Feb 5;118(3):410-9. doi: 10.1161/CIRCRESAHA.115.307298. Epub 2015 Dec 14.

10.

Genetic deletion of low density lipoprotein receptor impairs sterol-induced mouse macrophage ABCA1 expression. A new SREBP1-dependent mechanism.

Zhou X, He W, Huang Z, Gotto AM Jr, Hajjar DP, Han J.

J Biol Chem. 2008 Jan 25;283(4):2129-38. Epub 2007 Nov 20.

11.

Distinct functional domains contribute to degradation of the low density lipoprotein receptor (LDLR) by the E3 ubiquitin ligase inducible Degrader of the LDLR (IDOL).

Sorrentino V, Scheer L, Santos A, Reits E, Bleijlevens B, Zelcer N.

J Biol Chem. 2011 Aug 26;286(34):30190-9. doi: 10.1074/jbc.M111.249557. Epub 2011 Jul 6.

12.

The LXR-Idol axis differentially regulates plasma LDL levels in primates and mice.

Hong C, Marshall SM, McDaniel AL, Graham M, Layne JD, Cai L, Scotti E, Boyadjian R, Kim J, Chamberlain BT, Tangirala RK, Jung ME, Fong L, Lee R, Young SG, Temel RE, Tontonoz P.

Cell Metab. 2014 Nov 4;20(5):910-8. doi: 10.1016/j.cmet.2014.10.001. Epub 2014 Nov 4.

13.

Reduced VLDL clearance in Apoe(-/-)Npc1(-/-) mice is associated with increased Pcsk9 and Idol expression and decreased hepatic LDL-receptor levels.

Ishibashi M, Masson D, Westerterp M, Wang N, Sayers S, Li R, Welch CL, Tall AR.

J Lipid Res. 2010 Sep;51(9):2655-63. doi: 10.1194/jlr.M006163. Epub 2010 Jun 18.

14.

IDOL stimulates clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor.

Scotti E, Calamai M, Goulbourne CN, Zhang L, Hong C, Lin RR, Choi J, Pilch PF, Fong LG, Zou P, Ting AY, Pavone FS, Young SG, Tontonoz P.

Mol Cell Biol. 2013 Apr;33(8):1503-14. doi: 10.1128/MCB.01716-12. Epub 2013 Feb 4.

15.

Identification of human low-density lipoprotein receptor as a novel target gene regulated by liver X receptor alpha.

Ishimoto K, Tachibana K, Sumitomo M, Omote S, Hanano I, Yamasaki D, Watanabe Y, Tanaka T, Hamakubo T, Sakai J, Kodama T, Doi T.

FEBS Lett. 2006 Sep 4;580(20):4929-33. Epub 2006 Aug 14.

16.

Stable liver-specific expression of human IDOL in humanized mice raises plasma cholesterol.

Ibrahim S, Somanathan S, Billheimer J, Wilson JM, Rader DJ.

Cardiovasc Res. 2016 May 1;110(1):23-9. doi: 10.1093/cvr/cvw010. Epub 2016 Jan 19.

17.

T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice.

Terasaka N, Hiroshima A, Koieyama T, Ubukata N, Morikawa Y, Nakai D, Inaba T.

FEBS Lett. 2003 Feb 11;536(1-3):6-11.

18.

Role of PCSK9 and IDOL in the pathogenesis of acquired LDL receptor deficiency and hypercholesterolemia in nephrotic syndrome.

Liu S, Vaziri ND.

Nephrol Dial Transplant. 2014 Mar;29(3):538-43. doi: 10.1093/ndt/gft439. Epub 2013 Oct 28.

PMID:
24166456
19.

A nuclear receptor corepressor-dependent pathway mediates suppression of cytokine-induced C-reactive protein gene expression by liver X receptor.

Blaschke F, Takata Y, Caglayan E, Collins A, Tontonoz P, Hsueh WA, Tangirala RK.

Circ Res. 2006 Dec 8;99(12):e88-99. Epub 2006 Nov 16.

20.

An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway.

Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS.

Cancer Discov. 2011 Oct;1(5):442-56. doi: 10.1158/2159-8290.CD-11-0102. Epub 2011 Sep 15. Erratum in: Cancer Discov. 2012 Feb;2(2):290-1.

Supplemental Content

Support Center